A major new study published in JAMA (December 2025)—the WISDOM Trial—is reshaping how we think about breast cancer screening. Instead of recommending annual mammograms for every woman over 40, the WISDOM Study tested whether personalized, risk‑based screening could be just as safe while reducing unnecessary tests for low‑risk women and increasing appropriate monitoring for high‑risk women. The future may also allow for all the organizations to agree on strategies, a defect in American medicine which complicates care as women juggle what they read, what the gyno says, and what their PCP says.
The WISDOM Study and the Future of Breast Cancer Screening
Many women have already moved to every two years. But we have also extended screening to age 90 or above! That’s a lot of screening time, expense, and radiation exposure. As we move to personalized medicine we need to fine tune breast cancer screening for individuals. The WISDOM Trial (“Women Informed to Screen Depending on Measures of Risk”) compared:
- Annual screening for all women starting at age 40
vs. - Risk‑based screening, where screening schedules were tailored based on:
- Genetic risk (pathogenic variants + polygenic risk score)
- Breast density
- Family history
- Clinical risk models [jamanetwork.com]
We still haven’t added in obesity, diet, fitness levels, hormone use, smoking history, alcohol history, pregnancy, breastfeeding history, all of which affects rates of breast cancer and offer further ways to improve the accuracy of screening.
Over 28,372 women aged 40–74 were randomized from across the U.S. [thewisdomstudy.org]
🔍 Key Findings
1. Risk‑based screening was just as safe as annual mammograms.
- Rates of stage ≥ IIB breast cancers—a critical measure of dangerous cancers—were noninferior in the risk‑based group (30 per 100,000 person‑years vs 48 in annual screening). [thewisdomstudy.org]
2. High‑risk women benefited the most.
Women in the highest risk group, who were screened every 6 months with alternating mammogram + MRI, had no stage ≥ IIB cancers detected. [jamanetwork.com]
3. Low‑risk women safely received fewer mammograms.
Risk‑based screening recommended:
- No screening before age 50 for women 40–49 with very low risk
- Biennial screening for average‑risk women [medicalxpress.com]
This helps limit the downsides of mammography—false positives, unnecessary biopsies, expense, and added anxiety—without compromising safety.
4. Biopsy rates were similar between groups.
Biopsies did not decrease overall (1029 vs 943), likely because high‑risk women actually underwent more imaging. [thewisdomstudy.org]
5. Risk‑based screening improved prevention uptake.
Among the highest‑risk women, use of preventive therapies nearly doubled. [thewisdomstudy.org]
🧬 Why This Matters
Traditional age‑based screening assumes all women have similar risk. But risk can vary 10‑fold or more based on genetics, breast density, and other factors. The WISDOM results support what precision‑medicine experts have long argued: screening intensity should match actual risk. [medicalxpress.com]
This helps:
- Reduce unnecessary tests for low‑risk women
- Ensure high‑risk women get the more intensive screening they truly need
- Use healthcare resources more effectively
TIME Magazine highlighted one especially important clinical outcome: a one‑third reduction in Stage 2B cancers in the personalized screening group—exactly the cancers most associated with rising mortality. [time.com]
🧠 Bottom Line
The WISDOM Study demonstrates that personalized, risk‑based breast cancer screening is safe, acceptable to women, and potentially more effective at catching aggressive cancers earlier while reducing unnecessary imaging in low‑risk groups. There are also newer blood screening tests that use cell-free DNA methylation tests, and this could be added to risk-based screens, BUT it’s only good for very early cancers, potentially before they show up on mammograms and wouldn’t then change the mammogram frequencies.
This marks a major step toward modernizing breast cancer screening in the precision/personalized‑medicine era. [jamanetwork.com]
